News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Aradigm Corporation And Canadian Department Of National Defence Extend AERx Liposomal Ciprofloxacin Development Program
April 26, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Aradigm Corporation (NASDAQ: ARDM) today announced that Defence R&D Canada (DRDC) has extended the development program for the aerosolized delivery of liposome-encapsulated ciprofloxacin as a treatment for bioterror-related anthrax.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Layoff Tracker
Amgen Trims Horizon Subsidiary, f5 Shuts Down
March 11, 2026
·
33 min read
·
BioSpace Editorial Staff
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
March 11, 2026
·
1 min read
·
Heather McKenzie
C-suite
BioNTech Founders To Leave Famed mRNA Biotech for New Venture
March 10, 2026
·
2 min read
·
Annalee Armstrong
Manufacturing
Cell and Gene Therapy Manufacturing Market To Skyrocket to $146B by 2032
March 10, 2026
·
3 min read
·
Nick Paul Taylor
